Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 10/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759452 | 0.68 | ALOX5 (0.39) | ALOX5 | |
| SCHEMBL13052438 | 0.67 | ALOX5 (0.38) | ALOX5 | |
| SCHEMBL6900210 | 0.65 | ALOX5 (0.44) | ALOX5ESR1ESR2NUAK1IGF1R | |
| SCHEMBL8780350 | 0.65 | ALOX5 (0.36) | ALOX5 | |
| SCHEMBL8780352 | 0.65 | ALOX5 (0.36) | ALOX5 | |
| Durohydroquinone SCHEMBL69786 | 0.64 | ALOX5 (0.38) | ALOX5 | |
| SCHEMBL8778668 | 0.63 | ALOX5 (0.35) | ALOX5 | |
| SCHEMBL8778673 | 0.62 | ALOX5 (0.34) | ALOX5ESR1ESR2 | |
| SCHEMBL6904469 | 0.61 | ALOX5 (0.36) | ALOX5 | |
| SCHEMBL6905384 | 0.61 | ALOX5 (0.44) | ALOX5ESR1ESR2NUAK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297262-A1 | PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES | COLBY PHARMACEUTICAL COMPANY (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297262-A1 | PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES | COLBY PHARMACEUTICAL COMPANY (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010121177-A2 | PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES | COLBY PHARMACEUTICAL COMPANY (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010046259-A1 | POLYCYCLIC COMPOUNDS FOR ELECTRONIC APPLICATIONS | BASF SE (DE) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297262-A1 | PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES | MPO, HMOX1, LPO | ALOX5 103/4885ESR1 1655/4885ESR2 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.